FEB 15, 2018 12:59 PM PST

Cancer-Killing Virus Collaborates with the Human Immune System

WRITTEN BY: Kara Marker

An unlikely collaboration between a virus and the human immune system is working to address a common enemy: cancer. From the University of California San Francisco (UCSF), researchers are working with biotech professionals to understand why it’s possible to create cancer vaccines out of viruses that kill tumors and activate the immune system.

High magnification micrograph of a acinar cell carcinoma of the pancreas. Credit: Wikimedia user Nephron

Scientists first noticed the relationship between viral infections and cancer depletion a century ago, yet the first oncolytic viral therapy to be approved by the FDA was only in 2015. Now, scientists want to understand more about how viruses in cancer vaccines work to both kill cancer cells and activate the immune system against cancer. Additionally, there could be ways to combine the cancer vaccine approach with existing cancer immunotherapy drugs.

UCSF researchers collaborated with experts from SillaJen Biotherapeutics Inc. SillaJen is developing an oncolytic viral therapy called Pexa-Vec for use in primary liver and colorectal cancers. It is based on a virus engineered from the harmless vaccinia cowpox virus, the key ingredient of the very first vaccine, the vaccine to prevent smallpox. In the context of Pexa-Vec, the virus attacks cancer by cutting off the tumor supply to blood vessels.

“This virus could be given systemically by intravenous injection, in contrast to most oncolytic viruses that are injected into the tumor itself, which obviously limits their therapeutic potential against cancers that are inaccessible or have spread to multiple sites in the body," explained UCSF’s Donald McDonald, MD, PhD.

Using an animal model of neuroendocrine pancreatic cancer, researchers injected Pexa-Vec into mice to identify the ways the virus worked to kill cancer cells and if there were opportunities to improve it.

They saw that the virus did not infect healthy organs or cause illness, but it did infect blood vessels in tumors. This infection exposed tumor proteins to both the virus and the immune system, activating CD8+ T cells, also known as cytotoxic T cells.

The virus directly killed some tumor cells (five percent), but the majority of the tumor destruction was directed by the immune system five days after injection.

"The question with immunotherapy has always been - why doesn't the immune system naturally detect and attack cancer cells?" McDonald said. "It seems like these viruses are like setting off a bomb that jars the immune system. The infection releases tumor antigens in a way that jump-starts the immune response."

Next, the researchers tested the impact of combining the cancer vaccine with an additional immunotherapy drug called sunitinib, which inhibits blood vessel growth in tumors and influences the immune system. Together with the cancer vaccine, sunitinib greatly enhanced the number of tumor cells killed. The drug does this indirectly, researchers found, by boosting the activation of the immune system in response to tumor proteins exposed by the cancer vaccine virus.

“Pexa-Vec is working like a vaccine to sensitize the immune system to attack cancer," said James Burke, CMO of SillaJen Biotherapeutics. “If the virus is igniting a fire within the tumor, we want to see if we can use these immune modulators to pour gas on the flames."

The present study was published in the journal Cancer Research.

Source: University of California San Francisco

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
AUG 27, 2020
Immunology
A Seaweed-Inspired Shuttle for Delivering a Stem Cell Cargo
AUG 27, 2020
A Seaweed-Inspired Shuttle for Delivering a Stem Cell Cargo
  Living medicines in the form of stem cell therapies have immense potential for their ability to regenerate and he ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 12, 2020
Genetics & Genomics
The Malaria Parasite Can Change Host Cell Genetics
OCT 12, 2020
The Malaria Parasite Can Change Host Cell Genetics
Mosquitoes can transmit the malaria-causing Plasmodium parasite to humans. Malaria was estimated to have caused the deat ...
OCT 22, 2020
Immunology
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
OCT 22, 2020
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more pr ...
NOV 04, 2020
Coronavirus
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
NOV 04, 2020
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
COVID-19, the illness caused by the pandemic virus SARS-CoV-2, is known to cause blood clots all over the body in some p ...
Loading Comments...